A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction - Related Studies

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction

This study has been completed.

Study NCT00001298. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Kidney Diseases

2	More general conditions related to this trial
		Urologic Diseases

3	Interventions listed in this trial
		carboxypeptidase-G2

4	Additional drug interventions recognized in this trial
		Methotrexate

5	More general drug interventions related to this trial
		Abortifacient Agents
		Abortifacient Agents, Nonsteroidal
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antirheumatic Agents
		Dermatologic Agents
		Enzyme Inhibitors
		Folic Acid Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Reproductive Control Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		National Cancer Institute (NCI)